Hairy cell Leukemia, Version 2.2018: Clinical practice guidelines in oncology

William G. Wierda; John C. Byrd; Jeremy S. Abramson; Seema Bhat; Greg Bociek; Danielle Brander; Jennifer Brown; Asher Chanan-Khan; Steve E. Coutre; Randall S. Davis; Christopher D. Fletcher; Brian Hill; Brad S. Kahl; Manali Kamdar; Lawrence D. Kaplan; Nadia Khan; Thomas J. Kipps; Jeffrey Lancet; Shuo Ma; Sami Malek; Claudio Mosse; Mazyar Shadman; Tanya Siddiqi; Deborah Stephens; Nina Wagner; Andrew D. Zelenetz

doi:10.6004/jnccn.2017.0165

Hairy cell Leukemia, Version 2.2018: Clinical practice guidelines in oncology

William G. Wierda, John C. Byrd, Jeremy S. Abramson, Seema Bhat, Greg Bociek, Danielle Brander, Jennifer Brown, Asher Chanan-Khan, Steve E. Coutre, Randall S. Davis, Christopher D. Fletcher, Brian Hill, Brad S. Kahl, Manali Kamdar, Lawrence D. Kaplan, Nadia Khan, Thomas J. Kipps, Jeffrey Lancet, Shuo Ma, Sami MalekClaudio Mosse, Mazyar Shadman, Tanya Siddiqi, Deborah Stephens, Nina Wagner, Andrew D. Zelenetz

Leukemia

Research output: Contribution to journal › Review article › peer-review

22 Scopus citations

Abstract

Hairy cell leukemia (HCL) is a rare type of indolent B-cell leukemia, characterized by symptoms of fatigue and weakness, or-ganomegaly, pancytopenia, and recurrent opportunistic infections. Classic HCL should be considered a distinct clinical entity separate from HCLvariant (HCLv), which is associated with a more aggressive disease course and may not respond to standard HCL therapies. Somatic hypermutation in the IGHV gene is present in most patients with HCL. The BRAF V600E mutation has been reported in most patients with classic HCL but not in those with other B-cell leukemias or lymphomas. Therefore, it is necessary to distinguish HCLv from classic HCL. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of classic HCL.

Original language	English (US)
Pages (from-to)	1414-1427
Number of pages	14
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	15
Issue number	11
DOIs	https://doi.org/10.6004/jnccn.2017.0165
State	Published - Nov 1 2017

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2017.0165

Cite this

Wierda, W. G., Byrd, J. C., Abramson, J. S., Bhat, S., Bociek, G., Brander, D., Brown, J., Chanan-Khan, A., Coutre, S. E., Davis, R. S., Fletcher, C. D., Hill, B., Kahl, B. S., Kamdar, M., Kaplan, L. D., Khan, N., Kipps, T. J., Lancet, J., Ma, S., ... Zelenetz, A. D. (2017). Hairy cell Leukemia, Version 2.2018: Clinical practice guidelines in oncology. JNCCN Journal of the National Comprehensive Cancer Network, 15(11), 1414-1427. https://doi.org/10.6004/jnccn.2017.0165

Wierda, WG, Byrd, JC, Abramson, JS, Bhat, S, Bociek, G, Brander, D, Brown, J, Chanan-Khan, A, Coutre, SE, Davis, RS, Fletcher, CD, Hill, B, Kahl, BS, Kamdar, M, Kaplan, LD, Khan, N, Kipps, TJ, Lancet, J, Ma, S, Malek, S, Mosse, C, Shadman, M, Siddiqi, T, Stephens, D, Wagner, N & Zelenetz, AD 2017, 'Hairy cell Leukemia, Version 2.2018: Clinical practice guidelines in oncology', JNCCN Journal of the National Comprehensive Cancer Network, vol. 15, no. 11, pp. 1414-1427. https://doi.org/10.6004/jnccn.2017.0165

@article{4f6719658e5347f381304c52ddb5981f,

title = "Hairy cell Leukemia, Version 2.2018: Clinical practice guidelines in oncology",

abstract = "Hairy cell leukemia (HCL) is a rare type of indolent B-cell leukemia, characterized by symptoms of fatigue and weakness, or-ganomegaly, pancytopenia, and recurrent opportunistic infections. Classic HCL should be considered a distinct clinical entity separate from HCLvariant (HCLv), which is associated with a more aggressive disease course and may not respond to standard HCL therapies. Somatic hypermutation in the IGHV gene is present in most patients with HCL. The BRAF V600E mutation has been reported in most patients with classic HCL but not in those with other B-cell leukemias or lymphomas. Therefore, it is necessary to distinguish HCLv from classic HCL. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of classic HCL.",

author = "Wierda, {William G.} and Byrd, {John C.} and Abramson, {Jeremy S.} and Seema Bhat and Greg Bociek and Danielle Brander and Jennifer Brown and Asher Chanan-Khan and Coutre, {Steve E.} and Davis, {Randall S.} and Fletcher, {Christopher D.} and Brian Hill and Kahl, {Brad S.} and Manali Kamdar and Kaplan, {Lawrence D.} and Nadia Khan and Kipps, {Thomas J.} and Jeffrey Lancet and Shuo Ma and Sami Malek and Claudio Mosse and Mazyar Shadman and Tanya Siddiqi and Deborah Stephens and Nina Wagner and Zelenetz, {Andrew D.}",

note = "Publisher Copyright: {\textcopyright} JNCCN - Journal of the National Comprehensive Cancer Network.",

year = "2017",

month = nov,

day = "1",

doi = "10.6004/jnccn.2017.0165",

language = "English (US)",

volume = "15",

pages = "1414--1427",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "11",

}

TY - JOUR

T1 - Hairy cell Leukemia, Version 2.2018

T2 - Clinical practice guidelines in oncology

AU - Wierda, William G.

AU - Byrd, John C.

AU - Abramson, Jeremy S.

AU - Bhat, Seema

AU - Bociek, Greg

AU - Brander, Danielle

AU - Brown, Jennifer

AU - Chanan-Khan, Asher

AU - Coutre, Steve E.

AU - Davis, Randall S.

AU - Fletcher, Christopher D.

AU - Hill, Brian

AU - Kahl, Brad S.

AU - Kamdar, Manali

AU - Kaplan, Lawrence D.

AU - Khan, Nadia

AU - Kipps, Thomas J.

AU - Lancet, Jeffrey

AU - Ma, Shuo

AU - Malek, Sami

AU - Mosse, Claudio

AU - Shadman, Mazyar

AU - Siddiqi, Tanya

AU - Stephens, Deborah

AU - Wagner, Nina

AU - Zelenetz, Andrew D.

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Hairy cell leukemia (HCL) is a rare type of indolent B-cell leukemia, characterized by symptoms of fatigue and weakness, or-ganomegaly, pancytopenia, and recurrent opportunistic infections. Classic HCL should be considered a distinct clinical entity separate from HCLvariant (HCLv), which is associated with a more aggressive disease course and may not respond to standard HCL therapies. Somatic hypermutation in the IGHV gene is present in most patients with HCL. The BRAF V600E mutation has been reported in most patients with classic HCL but not in those with other B-cell leukemias or lymphomas. Therefore, it is necessary to distinguish HCLv from classic HCL. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of classic HCL.

AB - Hairy cell leukemia (HCL) is a rare type of indolent B-cell leukemia, characterized by symptoms of fatigue and weakness, or-ganomegaly, pancytopenia, and recurrent opportunistic infections. Classic HCL should be considered a distinct clinical entity separate from HCLvariant (HCLv), which is associated with a more aggressive disease course and may not respond to standard HCL therapies. Somatic hypermutation in the IGHV gene is present in most patients with HCL. The BRAF V600E mutation has been reported in most patients with classic HCL but not in those with other B-cell leukemias or lymphomas. Therefore, it is necessary to distinguish HCLv from classic HCL. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of classic HCL.

UR - http://www.scopus.com/inward/record.url?scp=85033802071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033802071&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2017.0165

DO - 10.6004/jnccn.2017.0165

M3 - Review article

C2 - 29118233

AN - SCOPUS:85033802071

SN - 1540-1405

VL - 15

SP - 1414

EP - 1427

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 11

ER -

Hairy cell Leukemia, Version 2.2018: Clinical practice guidelines in oncology

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this